EPIX Pharmaceuticals , Second Discovery Program in Collaboration with GlaxoSmithKline

Nov. 5, 2007-... In December 2006, EPIX and GSK announced a worldwide multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including EPIX's novel 5-HT4 partial agonist program, PRX-03140, which is in early-stage clinical development for the treatment of Alzheimer's disease... EPIX 's Press Release -